SCYNEXIS Inc
Company Profile
Business description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Contact
1 Evertrust Plaza
13th Floor
Jersey CityNJ07302 - 6548
USAT: +1 201 884-5485
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
29
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
stocks
The sectors set to soar on government spending
stocks
Chart of the Week: How private companies are reshaping public markets
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,031.70 | 45.20 | -0.50% |
| CAC 40 | 7,983.20 | 91.03 | -1.13% |
| DAX 40 | 23,819.06 | 85.04 | 0.36% |
| Dow JONES (US) | 47,231.49 | 79.51 | -0.17% |
| FTSE 100 | 9,716.42 | 19.36 | -0.20% |
| HKSE | 26,241.83 | 244.07 | -0.92% |
| NASDAQ | 23,053.99 | 445.80 | -1.90% |
| Nikkei 225 | 50,276.37 | 607.31 | -1.19% |
| NZX 50 Index | 13,599.21 | 22.40 | 0.16% |
| S&P 500 | 6,780.50 | 15.79 | -0.23% |
| S&P/ASX 200 | 8,769.70 | 40.80 | -0.46% |
| SSE Composite Index | 3,997.56 | 10.20 | -0.25% |